We also observed significantly increased incidence risks of thyroid cancer and thyroid dysfunction in the GLP‐1 RAs patients, and these risks also increased in a manner directly proportional to the duration of GLP‐1 RAs therapy. Here, GLP1R is linked to thyroid gland carcinoma.